Nanobiotix secures €9m funding from bpifrance to advance NBTXR3 development
Granted through bpifrance’s Strategic Industrial Innovation (ISI) program, the funding is to expedite the clinical and industrial development of NBTXR3 in a new indication, liver cancer. Liver cancer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.